Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now later-stage tilt small index

Follicular Lymphoma With Unusual Cytological Features: later-stage trial registry

1 of 1 indexed Follicular Lymphoma With Unusual Cytological Features trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Follicular Lymphoma With Unusual Cytological Features: 1 US clinical trial tracked, 1 recruiting.

Follicular Lymphoma With Unusual Cytological Features is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 1 of these trials.

Enrollment posture brief

Registry condition follicular-lymphoma-with-unusual-cytological-features

OPEN 1 | RECR 100% | LATE 1 | EARLY 0 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Follicular Lymphoma With (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Follicular Lymphoma With Unusual Cytological Features

Follicular Lymphoma With Unusual Cytological Features lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Follicular Lymphoma With Unusual Cytological Features on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Follicular Lymphoma With Unusual Cytological Features is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 31

Phase Distribution

PhaseTrial count
Phase 3 1

Top Sponsors

Named interventions

Most-linked intervention names on Follicular Lymphoma With Unusual Cytological Features records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Mosunetuzumab Biological
1 trials
Rituximab Biological
1 trials
Positron Emission Tomography Procedure
1 trials
Computed Tomography Procedure
1 trials
Biospecimen Collection Procedure
1 trials

US sites by state

Facility locations filed on Follicular Lymphoma With Unusual Cytological Features trials. A trial with sites in several states counts in each.

Colorado 1 trials
California 1 trials
Arizona 1 trials
Arkansas 1 trials
Alabama 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Follicular Lymphoma With Unusual Cytological Features page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Follicular Lymphoma With Unusual Cytological Features trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • National Cancer Institute (NCI) sponsors the most Follicular Lymphoma With Unusual Cytological Features trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Follicular Lymphoma With Unusual Cytological Features condition card totals 1 registered trials; most-linked intervention Mosunetuzumab; top US site state Colorado. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.